Department of Nephrology, Hôpital Edouard Herriot and Unité, Université de Lyon, Lyon, France.
J Nephrol. 2010 Jul-Aug;23(4):387-98.
Contrast-induced acute kidney injury (CIAKI) refers to a sudden deterioration in renal function associated with the use of iodinated contrast media. CIAKI can lead to increased morbidity and mortality. Risk of CIAKI is low in the general population but increased in patients with risk factors, which include chronic kidney disease (particularly secondary to diabetes mellitus) and advanced age. Screening for risk factors and implementation of prevention practices in at-risk patients is recommended. Patients at risk of CIAKI because of chronic kidney disease can be identified by serum creatinine measurement, although, preferably, this should be applied to estimate glomerular filtration rate; screening questionnaires or risk scoring can also identify at-risk patients. Current best practice calls for intravenous periprocedural volume expansion in at-risk patients, but this is not practical in all clinical settings. No pharmacological approach has been demonstrated to offer consistent protection. Volume/dose of contrast agent should be the lowest needed to achieve a diagnostic result. The use of iso-osmolar contrast media is recommended for high-risk patients, because recent controlled clinical trials in coronary procedure settings have shown a lower nephrotoxicity of iodixanol, as compared with several low-osmolar contrast agents. However, additional studies involving a larger selection of iso- and low-osmolar contrast media are needed, particularly with intravenous use for computed tomography scans, if their use in this patient population is to be optimized.
对比剂诱导的急性肾损伤(CIAKI)是指与碘造影剂使用相关的肾功能突然恶化。CIAKI 可导致发病率和死亡率增加。一般人群 CIAKI 的风险较低,但在有危险因素的患者中风险增加,包括慢性肾脏病(尤其是继发于糖尿病)和高龄。建议对高危患者进行危险因素筛查和预防措施。可通过血清肌酐测量识别因慢性肾脏病而 CIAKI 风险增加的患者,但最好应用该方法估计肾小球滤过率;也可通过筛查问卷或风险评分识别高危患者。目前的最佳实践要求高危患者在围手术期静脉补液扩容,但并非所有临床情况下均可行。尚无药物方法被证明可提供一致的保护。应使用达到诊断效果所需的最低剂量对比剂。建议高危患者使用等渗造影剂,因为最近在冠状动脉介入治疗中进行的对照临床试验显示,与几种低渗造影剂相比,碘克沙醇的肾毒性较低。然而,如果要优化此类患者人群的使用,还需要开展更多涉及更大选择范围的等渗和低渗造影剂的研究,特别是静脉用于 CT 扫描的情况。